Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherRevenue - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuancesWages, Salaries and Other
Ratios

Nuvation Bio (NUVB) Shares Outstanding (2022 - 2026)

Nuvation Bio has reported Shares Outstanding over the past 5 years, most recently at $346.7 million for Q1 2026.

  • Quarterly Shares Outstanding rose 2.32% to $346.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $346.7 million through Mar 2026, up 2.32% year-over-year, with the annual reading at $1.0 million for FY2025, 99.7% down from the prior year.
  • Shares Outstanding was $346.5 million for Q1 2026 at Nuvation Bio, roughly flat from $346.5 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $346.5 million in Q4 2025 and troughed at $1.0 million in Q2 2023.
  • The 5-year median for Shares Outstanding is $218.1 million (2023), against an average of $208.4 million.
  • The largest YoY upside for Shares Outstanding was 34075.64% in 2025 against a maximum downside of 99.7% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $217.6 million in 2022, then grew by 0.19% to $218.0 million in 2023, then skyrocketed by 54.48% to $336.8 million in 2024, then crashed by 99.7% to $1.0 million in 2025, then surged by 34569.33% to $346.7 million in 2026.
  • Per Business Quant, the three most recent readings for NUVB's Shares Outstanding are $346.7 million (Q1 2026), $1.0 million (Q4 2025), and $341.8 million (Q3 2025).